| 摘要 |
New 3-substituted 4-(phenyl-N-alkyl)-piperazine and 4-(phenyl-N-alkyl)-piperidine compounds of Formula (1), wherein X N, CH, or C, however X may only be C when the compound comprises a double bond at the dotted line; R<SUB>1 </SUB>is OSO<SUB>2</SUB>CF<SUB>3</SUB>, OSO<SUB>2</SUB>CH<SUB>3</SUB>, SOR<SUB>3</SUB>, SO<SUB>2</SUB>R<SUB>3</SUB>, COR<SUB>3</SUB>, NO<SUB>2</SUB>, or CONHR<SUB>3 </SUB>and when X is CH or C R<SUB>1 </SUB>may also be CF<SUB>3</SUB>, CN, F, Cl, Br, or I; R<SUB>2 </SUB>is a C<SUB>1</SUB>-C<SUB>4 </SUB>alkyl, an allyl, CH<SUB>2</SUB>SCH<SUB>3</SUB>, CH<SUB>2</SUB>CH<SUB>2</SUB>OCH<SUB>3</SUB>, CH<SUB>2</SUB>CH<SUB>2</SUB>CH<SUB>2</SUB>F, CH<SUB>2</SUB>CF<SUB>3</SUB>, 3,3,3-trifluoropropyl, 4,4,4,-trifluorobutyl, or -(CH<SUB>2</SUB>)-R<SUB>4</SUB>; R<SUB>3 </SUB>is a C<SUB>1</SUB>-C<SUB>3 </SUB>alkyl CF<SUB>3</SUB>, or N(R<SUB>2</SUB>)<SUB>2</SUB>; R<SUB>4 </SUB>is a C<SUB>3</SUB>-C<SUB>6 </SUB>cycloalkyl, 2-tetrahydrofurane or 3-tetra-hydrofurane, as well as pharmaceutically acceptable salts thereof are disclosed. Also pharmaceutical compositions comprising the above compounds and methods wherein the above compounds are used for treatment of disorders in the central nervous system are disclosed
|
